313 related articles for article (PubMed ID: 27139908)
1. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.
Moran-Jones K
Mol Diagn Ther; 2016 Jun; 20(3):199-212. PubMed ID: 27139908
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
[TBL] [Abstract][Full Text] [Related]
3. [Expressions of MACC1, HGF, and C-met protein in epithelial ovarian cancer and their significance].
Zhang RT; Shi HR; Huang HL; Chen ZM; Liu HN; Yuan ZF
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1551-5. PubMed ID: 21945764
[TBL] [Abstract][Full Text] [Related]
4. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.
Bu R; Uddin S; Bavi P; Hussain AR; Al-Dayel F; Ghourab S; Ahmed M; Al-Kuraya KS
Lab Invest; 2011 Jan; 91(1):124-37. PubMed ID: 20661229
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
Phan LM; Fuentes-Mattei E; Wu W; Velazquez-Torres G; Sircar K; Wood CG; Hai T; Jimenez C; Cote GJ; Ozsari L; Hofmann MC; Zheng S; Verhaak R; Pagliaro L; Cortez MA; Lee MH; Yeung SC; Habra MA
Cancer Res; 2015 Oct; 75(19):4131-42. PubMed ID: 26282167
[TBL] [Abstract][Full Text] [Related]
6. Targeting the hepatocyte growth factor-cMET axis in cancer therapy.
Blumenschein GR; Mills GB; Gonzalez-Angulo AM
J Clin Oncol; 2012 Sep; 30(26):3287-96. PubMed ID: 22869872
[TBL] [Abstract][Full Text] [Related]
7. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression.
Noguchi E; Saito N; Kobayashi M; Kameoka S
Mol Med Rep; 2015 May; 11(5):3423-31. PubMed ID: 25592281
[TBL] [Abstract][Full Text] [Related]
9. HGF/MET signaling in ovarian cancer.
Zhou HY; Pon YL; Wong AS
Curr Mol Med; 2008 Sep; 8(6):469-80. PubMed ID: 18781954
[TBL] [Abstract][Full Text] [Related]
10. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
11. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
12. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
[TBL] [Abstract][Full Text] [Related]
13. Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy.
Serilmez M; Özgür E; Karaman S; Gezer U; Duranyıldız D
Cancer Biomark; 2019; 25(2):177-184. PubMed ID: 31104010
[TBL] [Abstract][Full Text] [Related]
14. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
Klotz DM; Link T; Wimberger P; Kuhlmann JD
Mol Oncol; 2021 Dec; 15(12):3626-3638. PubMed ID: 33738970
[TBL] [Abstract][Full Text] [Related]
16. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
Gaule PB; Crown J; O'Donovan N; Duffy MJ
Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
[TBL] [Abstract][Full Text] [Related]
17. Treatment with Lingqi capsules suppresses colorectal cancer by inhibiting the hepatocyte growth factor/c‑Met signal transduction pathway.
Wang GS; Zhao JL; Li H
Mol Med Rep; 2015 Mar; 11(3):1865-70. PubMed ID: 25373931
[TBL] [Abstract][Full Text] [Related]
18. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.
Kim KH; Kim H
Exp Mol Med; 2017 Mar; 49(3):e307. PubMed ID: 28336955
[TBL] [Abstract][Full Text] [Related]
19. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.
Nakamura M; Ono YJ; Kanemura M; Tanaka T; Hayashi M; Terai Y; Ohmichi M
Gynecol Oncol; 2015 Nov; 139(2):345-54. PubMed ID: 26335595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
